Semaglutide Outperforms Insulin Aspart for Blood Sugar Control and Vascular Health in Type 2 Diabetes

In 80 hospitalized type 2 diabetes patients, semaglutide (added to metformin) produced significantly better glycemic control than insulin aspart after three months. The semaglutide group achieved lower fasting blood glucose (6.13±0.68 vs. control, P<0.05) and 2-hour postprandial glucose (9.01±0.53 mmol/L vs. control, P<0.05). Patients on semaglutide reached target blood glucose faster (3.88±0.69 days vs. 5.73±1.01 days, P<0.05). Beyond glucose control, semaglutide lowered endothelin-1 (a vasoconstrictor), improved flow-mediated vasodilation (FMD), and improved insulin resistance as measured by HOMA-IR. C-peptide levels — a marker of the pancreas's own insulin production — were also assessed as part of the metabolic panel.

Prospective controlled study of 80 hospitalized T2DM patients (January 2022–December 2023). All patients received oral metformin. The control group added subcutaneous insulin aspart; the observation group added subcutaneous semaglutide. Outcomes measured at baseline and 3 months included fasting blood glucose, 2-hour postprandial glucose, time to target glucose, serum endothelin-1, flow-mediated dilation, fasting C-peptide, fasting insulin, and HOMA-IR.

This study adds to the evidence that semaglutide does more than lower blood sugar. The improvements in vascular function (lower ET-1, higher FMD) suggest cardiovascular benefits beyond glycemic control. The faster time to target glucose is clinically meaningful for hospitalized patients. It also provides comparative data against a standard insulin regimen.

Semaglutide is already one of the most prescribed GLP-1 drugs worldwide. This study contributes to the growing evidence that its benefits extend beyond glucose control to cardiovascular protection — specifically improved vasodilation and reduced endothelin-1. As the field moves toward recognizing type 2 diabetes as a cardiometabolic disease, drugs that address both glucose and vascular function simultaneously become increasingly valuable.

Relatively small sample size of 80 patients. Single-center study with hospitalized patients, which may not reflect outpatient populations. The abstract does not specify whether randomization was used. Published in a lower-impact journal. Three-month follow-up is relatively short for assessing long-term metabolic and vascular outcomes.